Advair gains COPD indications

The FDA has approved Advair Diskus 250/50 (fluticasone propionate 250mcg and salmeterol 50mcg inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD) who have a history of exacerbations. The FDA has also expanded the use of Advair Diskus 250/50 to a broader patient population which includes not only patients with COPD associated with chronic bronchitis, but also emphysema or both conditions.

Advair Diskus 250/50 is already indicated for the maintenance treatment of asthma in patients not adequately controlled on other asthma-controller medications or whose disease severity warrants initiation of 2 maintenance therapies.

For more information call (888) 825-5249 or visit www.advair.com.